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ABSTRACT
Objective: A sensitive, rapid, accurate, and precise stability indicating high-performance liquid chromatography method was developed and validated 
for the simultaneous estimation of metformin (MET) and ertugliflozin (ERT).
Methods: The planned chromatographic method was developed using Kromasil C18 column using 0.1 M sodium dihydrogen phosphate methanol 
(50:50, by volume, pH 4.0) as mobile phase system followed by peak area response measurement at 238 nm. The developed method was validated by 
means of ICH guidelines about system suitability, linearity, sensitivity, selectivity, accuracy, precision, robustness, and specificity.
Results: Calibration curves of MET and ERT are linear from 250 to 750 µg/ml and 3.75 to 11.25 µg/ml, respectively. Relative standard deviation is 
<2.0% and recovery is ̴ 100%. Successfully, the developed method was applied for the simultaneous determination of MET and ERT in tablets and 
to study degradation of MET and ERT in acidic, alkaline, oxidation, thermal, and photolytic degradation conditions. No obstructions from additional 
common excipients of tablets and degradants were observed.
Conclusion: The results recommended method suitability for the analysis of MET and ERT in quality control laboratories.
Keywords: Antidiabetic agents, Metformin, Ertugliflozin, Degradation, Analysis.
INTRODUCTION
Ertugliflozin (ERT) is a selective inhibitor for sodium needy glucose 
cotransporters [1]. This cotransporter is responsible for reabsorption 
of glucose from glomerulus. ERT is prescribed for patients (adults) with 
Type II diabetes for controlling blood glucose level [2,3]. ERT belongs 
to gliflozins class of drug and is chemically described as (1S, 2S, 3S, 4R, 
5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-
dioxabicyclo[3.2.1]octane-2,3,4-triol (Fig. 1).
Metformin (MET) is an antihyperglycemic drug which belongs to the 
biguanide category [4]. MET is an approved medication prescribed 
for the treatment of Type II diabetes. MET controls blood glucose 
level by decreasing hepatic production of glucose, decreasing 
gastrointestinal absorption of glucose, and increasing target cell 
sensitivity to insulin [5-7]. Chemically, MET is described as N,N-
dimethylimidodicarbonimidic diamide (Fig. 1).
A fixed combination of ERT and MET was approved by FDA to control 
blood glucose level in Type II diabetic patients [8,9]. ERT and MET 
combination is used in addition to exercise and diet. ERT and MET 
combination is used for diabetic patients who are not satisfactorily 
controlled with a dosage containing ERT or MET alone.
A detailed survey for literature on ERT and MET combination reveals 
that no reported high-performance liquid chromatography (RP-
HPLC) method for the assay of two drugs in combination. The current 
investigation aims at developing and validating rapid, simple, sensitive, 
accurate, and reproducible stability indicating RP-HPLC method to 




ERT and MET reference standard drugs were supplied by Lara drugs Pvt. 
Ltd., Hyderabad, India, and Rainbow Pharma Training Labs, Hyderabad, 
India. Segluromet™ (ERT 7.5 mg and MET 500 mg) tablets by Merck 
and Co., Inc., USA. Hydrogen peroxide, orthophosphoric acid, sodium 
dihydrogen phosphate, hydrochloric acid, and sodium hydroxide were 
purchased from Sd. Fine Chemicals Ltd., Mumbai, India. Methanol was 
purchased from Merck India Ltd., Mumbai, India. Water was acquired 
from a Milli-Q water system (Millipore, USA). For filtration of samples 
and mobile phase, 0.45 μm membrane filter was used.
Instruments and HPLC conditions
A waters alliance HPLC system (2695 module) coupled with photodiode 
array detector and equipped with an autosampler, degasser and column 
oven were used for the analysis. Empower 2 software was employed 
for data acquisition. Separation was performed using a Kromasil C18 
column (250 mm×4.6 mm) with a particle size of 5.0 μm. The mobile 
phase consisting of 0.1 M sodium dihydrogen phosphate:methanol 
(50:50 v/v, pH 4.0) was delivered at 1.0 ml/minutes flow rate. Injection 
volume was 10 µl; detection wavelength was set at 238 and a total run 
time of 8 min. For quantification, the peak area response of ERT and 
MET was compared with corresponding calibration curves, wherein 
the peak area response of the calibration standards was plotted against 
their concentrations.
Preparation of stock and calibration standard solutions
ERT and MET stock solution was prepared in diluent (mobile phase) 
at a concentration of 5000 µg/ml (ERT) and 75 µg/ml (MET). Till its 
use, the stock solution was stored at 4°C. The calibration standard 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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solutions were made by successive dilution of the stock solution at the 
concentration ranges of 250–750 µg/ml and 3.75–11.25 µg/ml for ERT 
and MET, respectively.
Calibration graph
Five calibration solutions in the concentration range 250–750 µg/ml 
(MET) and 3.75–11.25 μg/ml (ERT and MET) were analyzed by the 
proposed method. For quantification, the peak area response of ERT 
and MET was compared with corresponding calibration curves, wherein 
the peak area response of the calibration standards was plotted against 
their concentrations. The intercepts and slopes of the calibration lines 
were also determined.
Assay of ERT and MET in combined tablet form
Ten tablets were weighed and powdered. Tablet powder corresponding 
to 500 mg of MET and 7.5 mg of ERT was transferred into 100 ml 
flask. 30 mL of mobile phase was added and then mixed. The solution 
was sonicated for 15 min and diluted to mark with mobile phase. 
The resultant solution was filtered using a 0.45 µm membrane filter 
and was appropriately diluted to get the test sample solution having 
7.5 µg/ml (ERT) and 500 µg/ml (MET). Test sample solution (10 μl) 
was injected into the system and was analyzed using described HPLC 
conditions. The assay was repeated 3 times. The peak areas of ERT and 
MET were measured. The percentage of ERT and MET was calculated 
using a regression equation which was derived from the corresponding 
calibration curve.
Forced degradation studies
This was done by the following guidelines of an international conference 
on harmonization [10].
Acidic hydrolysis
An aliquot (10 ml) of tablet sample stock solution (75 μg/ml of ERT and 
5000 µg/ml of MET) was transferred into 100 ml each volumetric flask, 
and then 10 ml of 0.1 N HCl was added. The contents of the flask were 
sonicated at room temperature for 30 min. Then, the flasks were cooled 
to room temperature, neutralized (by adding 0.1N NaOH) and diluted 
to 100 ml with mobile phase. Further, dilution with mobile phase was 
done to get 7.5 µg/ml for ERT and 500 µg/ml for MET. After filtration 
through 0.45 µm membrane filter, an aliquot (10 µl) from the solution 
was injected into the HPLC system. The proposed assay procedure is 
explained here.
Alkaline hydrolysis
An aliquot (10 ml) of tablet sample stock solution (75 µg/ml of ERT 
and 5000 µg/ml of MET) was transferred into 100 ml volumetric flasks, 
then 10 ml of 0.1 N NaOH was added. The flask with contents was 
allowed and sonicated at room temperature for 30 min. After cooling to 
room temperature, contents of the flasks were neutralized (by adding 
0.1N HCl) and completed with mobile phase till the volume. Later, the 
solution was diluted with methanol to obtain 7.5 μg/ml for ERT and 
500 µg/ml for MET, and then filtered using 0.45 µm membrane filter. An 
aliquot of 10 μl from the solution was applied into the HPLC system. The 
proposed assay procedure is explained here.
Oxidative degradation
An aliquot (10 ml) of tablet sample stock solution (75 µg/ml of ERT and 
5000 µg/ml of MET) was transferred into 100 ml volumetric flasks, and 
then 10 ml of 30% H2O2 was added. The flask was allowed for sonication 
at room temperature for 30 min and completed to 100 ml with mobile 
phase. To prepare the final concentration, further dilution was made 
with methanol to a concentration 7.5 µg/ml for ERT and 500 µg/ml for 
MET. After filtration through 0.45 µm membrane filter, 10 µl of solution 
was prepared and was applied into the HPLC system. The proposed 
assay procedure is explained here.
Thermal hydrolysis
Accurately weighed quantity of tablet powder corresponding to 500 mg 
of MET and 7.5 mg of ERT was placed in a Petrie dish. The Petric dish 
was heated in a hot air oven at 105°C for 30 min and was cooled to room 
temperature. The procedure is explained in section “Assay of ERT and 
MET in combined tablet form” is explained here.
Photolysis
An accurately weighed quantity of tablet powder equal to 500 mg of 
MET and 7.5 mg of ERT was placed in a Petrie dish. The Petric dish 
was kept under sunlight for 24 h. The Petric dish was cooled to room 
temperature, and this procedure is in section “Assay of ERT and MET in 
combined tablet form” is explained here.
RESULTS AND DISCUSSION
Method development
The experimental HPLC variables tested include the type of analytical 
column (Waters C18, Supelco C18, and Kromasil C18), type of buffer 
(orthophosphoric acid buffer and sodium dihydrogen phosphate buffer) 
pH of buffer (3, 4, and 5), percentage of methanol (40–60%), flow rate 
of mobile phase (0.8–1.2), and column temperature (25°C, 30°C, and 
35°C). The overall chromatographic conditions for the separation of 
the studied drug peaks with adequate sensitivity, resolution, and peak 
shape are summarized in Table 1. The chromatogram obtained using 
optimized HPLC conditions and is presented in Fig. 2.
Method validation
This was done following guidelines of an international conference on 
harmonization [11].
System suitability
This parameter was used to evaluate the reproducibility of the HPLC 
system for the analysis of ERT and MET. In this method, using five 
duplicate injections of a standard drug solution containing 7.5 µg/ml of 
ERT and 500 µg/ml of MET were used. The parameters calculated were 
peak area, retention time, plate count, resolution, and peak symmetry 
(Table 2).
Selectivity
Selectivity of the proposed method was weighed by comparing the 
chromatograms obtained from the mobile phase blank, placebo 
blank, and tablet sample (7.5 µg/ml-ERT and 500 µg/ml–MET) 
with the chromatogram obtained from the standard drug solution 
(7.5 μg/ml–ERT and 500 µg/ml–MET). The chromatograms of the 
studied samples are shown in Fig. 3. No interfering peak was observed 
at the retention time of ERT and MET. Thus, it proved the method’s 
selectivity.
Linearity and sensitivity
Herein work, linear calibration graphs for MET and ERT were 
constructed by plotting the peak area of MET and ERT against MET 
and ERT concentrations. Regression data were summarized in Table 3. 
Linear regression analysis data of calibration graphs proved to be good 
linear association between the concentrations of studied drugs and 
their corresponding peak areas. The method showed linearity over 
Table 1: HPLC parameters for the separation and analysis of ERT 
and MET
Parameter Particulars
Column Kromasil C18, 250 mm×4.6 mm 
i.d., and 5 µm particle size 
Column temperature 25°C
Mobile phase Sodium dihydrogen phosphate (pH 4.0; 
0.1M):methanol (50:50 v/v)
Flow rate 1.0 ml/min
Detection 238 nm
Injection volume 10 µl
Retention time MET – 2.481 min and ERT – 4.140 min
HPLC: High-performance liquid chromatography, MET: Metformin, 
ERT: Ertugliflozin
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Table 2: Test results for system suitability
Parameters Value obtained (mean of 5) RSD (%) Recommended value
Drug MET ERT MET ERT -
Retention time of drug (min) 2.480 4.135 0.046 0.105 RSD NMT 2%
Peak area of drug (mAU) 4786137 1246433 0.062 0.057 RSD NMT 2%
Plate count (N) 3659 7462 0.801 1.053 NLT 2000
Tailing factor (T) 1.428 1.523 0.313 0.293 NMT 2
Resolution (R) - 8.943 - 0.551 NLT 
RSD: Relative standard deviation, NMT: Not more than, NLT: Not less than, MET: Metformin, ERT: Ertugliflozin
Fig. 1: Structure of metformin and ertugliflozin
Fig. 2: Ertugliflozin and metformin chromatogram obtained using optimized high-performance liquid chromatography conditions
Fig. 3: Selectivity test chromatograms
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the concentration range of 250–750 µg/ml and 3.75–11.25 µg/ml 
with a regression coefficient of 0.9999 and 0.9997 for MET and ERT, 
respectively.
Using limit of detection (LOD) and limit of quantitation (LOQ), the 
sensitivity of the method was assessed. The LOD and LOQ were 
calculated following ICH guidelines [11] and are presented in Table 3. 
Results point out good sensitivity of the proposed method.
Precision and accuracy
Precision and accuracy of standard drug solution (7.5 µg/ml–ERT 
and 500 µg/ml–MET) were used to verify the reproducibility of 
the developed HPLC method. Five replicate measurements were 
documented. Accuracy and precision were expressed in terms 
of percentage assay and percentage relative standard deviation, 
respectively. The values for accuracy and precision are good enough 
according to the ICH guidelines [11] as shown in Table 4.
Recovery test
Recovery tests (to further evaluate method accuracy) were carried 
out by adding standard drug at three different levels (50%, 100%, and 
150% of label claim) to the preanalyzed sample solution [12,13]. The 
solutions were analyzed 3 times at each concentration level, using this 
method. The concentrations of MET and ERT were calculated from the 
corresponding calibration curve or regression equation. The results 
were shown in terms of percent recovery. Results shown in Table 5 
represent good accuracy and no interference from the excipients of the 
tablet dosage form.
Robustness
In the present work, robustness was checked by determining the result 
of small changes in the HPLC experimental parameters. The parameters 
were studied in mobile phase composition, pH of the mobile phase, 
column temperature, flow rate, and detection wavelength. It was 
observed that small differences in the HPLC experimental conditions 
did not considerably influence the results. This indicates that the new 
HPLC method is robust for the analysis of ERT and MET (Table 6).
MET and ERT forced degradation
Forced degradation testing of MET and ERT was carried out with 
tablet sample using ICH prescribed stress conditions [10]. Percentage 
degradation of MET and ERT under stress conditions applied was 
estimated and listed in Table 7. Degradation results indicate that ERT 
and MET are degraded more in thermal condition and less in oxidative 
condition. The retention times of degradants in all the conditions are 
present in Table 7. As the developed HPLC method could separate MET 
and ERT from their degradation products effectively, this method can 
be employed as a stability indicating method (Fig. 4). The MET and ERT 
peak purity was tested using a PDA detector. For peak purity testing, 
peak purity angle and peak purity threshold were determined in all the 
stress conditions. The values are shown in Table 7. MET and ERT peaks 
remain pure in all stressed samples using HPLC parameters.
Application of the developed HPLC method
The HPLC method is applied for the determination of MET and ERT 
in their combined tablet form. The results (Table 8) indicate that the 
developed HPLC method is suitable for the assay of MET and ERT 
with good recoveries and low relative standard deviation. There are 
no interferences from commonly encountered excipients. The results 
recommend this method for its suitability in the analysis of MET and 
ERT in quality control laboratories.
CONCLUSION
Validated stability indicates that the HPLC method was developed for 
analyzing MET and ERT simultaneously. This method demonstrated 
a linear range of 250–750 µg/ml and 3.75–11.25 µg/ml for MET 
and ERT, respectively. Total analyzing time was <9 min which 
proved the quickness of the proposed method. The method is able 
to quantify MET and ERT in the presence of forced degradation 
products selectively and specifically, and the result shows that this 
is stability indicating method. The present method is applied with 
good accuracy and precision for the quantitation of MET and ERT in 
tablets. The results recommend the suitability of the method for the 
analysis of MET and ERT in quality control laboratories.
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Linearity (µg/ml) 250–750 3.75–11.25
Regression 
equation




LOD (µg/ml) 0.563 0.038
LOQ (µg/ml) 1.878 0.127
PA: Peak area of drug, x: Concentration of drug, MET: Metformin, 
ERT: Ertugliflozin, LOD: Limit of detection, LOQ: Limit of quantitation
Table 4: Precision and accuracy of the proposed method
Drug Concentration (µg/ml) Peak area (mAU)* Determined (µg/ml)* Precision (%RSD)** Accuracy (%assay)*
MET 500 4784206 499.80 0.066 99.66
ERT 7.5 1244899 7.49 0.227 99.38
*Mean of five determined values; **relative standard deviation for five determined values, MET: Metformin, ERT: Ertugliflozin
Table 5: Recovery analysis of MET and ERT
Drug Spiked level Labeled claim (mg) Spiked (mg) Value obtained
Recovered (%)* RSD (%)**
MET 50 500 250 99.88 0.131
100 500 500 99.63 0.044
150 500 750 99.63 0.068
ERT 50 7.5 3.75 100.19 0.269
100 7.5 7.5 100.61 0.134
150 7.5 11.25 100.26 0.103
*Mean of three determined values; **relative standard deviation for three determined values, MET: Metformin, ERT: Ertugliflozin
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Table 6: Robustness test data for MET and ERT
Drug Investigated value Peak area (mAU) Plate count (N) Tailing factor (T) Resolution (R)
Mobile phase ratio: 0.1 M NaH2PO4: Methanol (50:50 v/v, optimized value)
MET 45:55 4,771,165 3601 1.30 -
55:45 4,792,696 3802 1.33 -
ERT 45:55 1,233,252 6930 1.42 8.65
55:45 1,250,643 7201 1.45 8.81
Mobile phase pH (4.0, optimized value)
MET 3.8 4,782,428 3663 1.41 -
4.2 4,881,354 3618 1.46 -
ERT 3.8 1,249,118 7350 1.54 8.90
4.2 1,254,448 7090 1.53 8.77
Flow rate of mobile phase (1.0 ml/min, optimized value)
MET 0.9 4,599,242 3537 1.30 -
1.1 4,651,165 3601 1.30 -
ERT 0.9 1,133,995 6559 1.39 8.53
1.1 1,193,252 6930 1.42 8.65
Column temperature (25°C, optimized value)
MET 23 4,862,696 3802 1.33 -
27 4,984,191 3932 1.33 -
ERT 23 1,310,643 7201 1.45 8.81
27 1,360,361 7557 1.50 9.05
Detection wavelength (238 nm, optimized value)
MET 236 5,240,786 3711 1.43 -
240 4,438,450 3659 1.42 -
ERT 236 1,109,055 7557 1.53 8.98
240 1,484,548 7559 1.53 8.99
MET: Metformin, ERT: Ertugliflozin
Fig. 4: Chromatograms of metformin and ertugliflozin after degradation
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Table 7: Forced degradation and peak purity test results of MET and ERT
Degradation type Drug Degradation (%) Purity angle Purity threshold Retention time of degradants (min)
Acidic hydrolysis MET 11.44 0.265 0.590 3.293 and 3.833
ERT 11.98 0.301 0.686
Alkaline hydrolysis MET 9.23 0.282 0.687 1.675 and 2.087
ERT 9.71 0.210 0.586
Oxidative degradation MET 8.39 0.378 0.787 1.453, 1.919, 2.138, 3.259, 3.728, 6.124, and 6.795
ERT 9.00 0.201 0.483
Thermal degradation MET 12.42 0.382 0.786 3.273, 3.798, 6.303, and 6.779
ERT 13.09 0.298 0.581
Photolysis MET 11.32 0.282 0.687 0.802, 1.568, 3.273, and 3.794
ERT 11.73 0.300 0.584
MET: Metformin, ERT: Ertugliflozin
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Labeled claim (mg) 500 7.50
Obtained value (mg)* 498.20 7.53
Recovery (%)* 99.64 100.46
RSD (%)** 0.080 0.081
*Mean of three determined values; **relative standard deviation for 3 
determined values, MET: Metformin, ERT: Ertugliflozin
